Hydroxyurea (HU), or hydroxycarbamide, is used for the treatment of some myeloproliferative and neoplastic diseases, and is currently the only drug approved by the FDA for use in sickle cell disease (SCD). Despite the relative success of HU therapy for SCD, a genetic disorder of the hemoglobin β chain that results in red-cell sickling, hemolysis, vascular inflammation and recurrent vasoocclusion, the exact mechanisms by which HU actuates remain unclear. We hypothesized that HU may modulate endothelial angiogenic processes, with important consequences for vascular inflammation. The effects of HU (50-200. μM; 17-24. h) on endothelial cell functions associated with key steps of angiogenesis were evaluated using human umbilical vein endothelial cell (HUVEC) cultures. Expression profiles of the HIF1A gene and the miRNAs 221 and 222, involved in endothelial function, were also determined in HUVECs following HU administration and the direct in vivo antiangiogenic effects of HU were assessed using a mouse Matrigel-plug neovascularization assay. Following incubation with HU, HUVECs exhibited high cell viability, but displayed a significant 75% inhibition in the rate of capillary-like-structure formation, and significant decreases in proliferative and invasive capacities. Furthermore, HU significantly decreased HIF1A expression, and induced the expression of miRNA 221, while downregulating miRNA 222. In vivo, HU reduced vascular endothelial growth factor (VEGF)-induced vascular development in Matrigel implants over 7. days. Findings indicate that HU is able to inhibit vessel assembly, a crucial angiogenic process, both in vitro and in vivo, and suggest that some of HU's therapeutic effects may occur through novel vascular mechanisms. © 2014 Elsevier Inc.94 106113Aliverti, V., Hydroxyurea as a reference standard in teratological screening. Comparison of the embryotoxic and teratogenic effects following single intraperitoneal or repeated oral administrations to pregnant rats (1980) Arch. Toxicol. Suppl., 4, pp. 239-247Brittain, J.E., Placenta growth factor in sickle cell disease: association with hemolysis and inflammation (2010) Blood, 115, pp. 2014-2020Charache, S., Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia (1992) Blood, 79, pp. 2555-2565Charache, S., Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (1995) N. Engl. J. Med., 332, pp. 1317-1322Chidlow, J.H., Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues (2007) Am. J. Physiol. Gastrointest. Liver Physiol., 293, pp. G5-G18Conran, N., Costa, F.F., Hemoglobin disorders and endothelial cell interactions (2009) Clin. Biochem., 42, pp. 1824-1838Costa, C., Angiogenesis and chronic inflammation: cause or consequence? (2007) Angiogenesis, 10, pp. 149-166Delaney, K.M., Leg ulcers in sickle cell disease: current patterns and practices (2013) Hemoglobin, 37, pp. 325-332Dobson, S.R., Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events (2002) Blood, 99, pp. 3144-3150Duits, A.J., Serum levels of angiogenic factors indicate a pro-angiogenic state in adults with sickle cell disease (2006) Br. J. Haematol., 134, pp. 116-119Elford, H.L., Effect of hydroxyurea on ribonucleotide reductase (1968) Biochem. Biophys. Res. Commun., 33, pp. 129-135Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease (1995) Nat. Med., 1, pp. 27-31Folkman, J., Angiogenesis: an organizing principle for drug discovery? (2007) Nat. Rev. Drug Discov., 6, pp. 273-286Guerreiro, S., Distinct modulation of alkaline phosphatase isoenzymes by 17beta-estradiol and xanthohumol in breast cancer MCF-7 cells (2007) Clin. Biochem., 40, pp. 268-273Healy, D.L., Angiogenesis: a new theory for endometriosis (1998) Hum. Reprod. Update, 4, pp. 736-740Hebbel, R.P., A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis (2009) Cardiovasc. Hematol. Disord. Drug Targets, 9, pp. 271-292Jackson, J.R., The codependence of angiogenesis and chronic inflammation (1997) FASEB J., 11, pp. 457-465Jain, R.K., Lessons from phase III clinical trials on anti-VEGF therapy for cancer (2006) Nat. Clin. Pract. Oncol., 3, pp. 24-40Jefferies, W.A., Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease (2013) Alzheimers Res. Ther., 5, p. 64Kato, G.J., Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes (2007) Blood Rev., 21, pp. 37-47Kersgard, C., Osswald, M.B., Hydroxyurea and sickle cell leg ulcers (2001) Am. J. Hematol., 68, pp. 215-216Kim, S.Y., Expression of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in sickle cell retina and choroid (2003) Exp. Eye Res., 77, pp. 433-445King, S.B., Nitric oxide production from hydroxyurea (2004) Free Radic. Biol. Med., 37, pp. 737-744Konisti, S., Hypoxia-a key regulator of angiogenesis and inflammation in rheumatoid arthritis (2012) Nat. Rev. Rheumatol., 8, pp. 153-162Koutroubakis, I.E., Role of angiogenesis in inflammatory bowel disease (2006) Inflamm. Bowel Dis., 12, pp. 515-523Kovacic, P., Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications (2011) Med. Hypotheses, 76, pp. 24-31Krupinski, J., Angiogenesis and inflammation in carotid atherosclerosis (2008) Front. Biosci., 13, pp. 6472-6482Landburg, P.P., Elevated circulating stromal-derived factor-1 levels in sickle cell disease (2009) Acta Haematol., 122, pp. 64-69Laurance, S., Hydroxycarbamide stimulates the production of proinflammatory cytokines by endothelial cells: relevance to sickle cell disease (2010) Pharmacogenet. Genomics, 20, pp. 257-268Lebensburger, J.D., Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model (2010) Haematologica, 95, pp. 1599-1603Lopes, F.C.M., Proangiogenic effects of plasma from sickle cell disease patients and antiangiogenic effects of hydroxyurea: evaluation of invasion and proliferation of human endothelial cells and effects of hydroxyurea in a mouse Matrigel plug neovascularization assay (2012) Blood, 120Matter, R.M., Serum angiogenin level in sickle cell disease and beta thalassemia patients (2014) Pediatr. Hematol. Oncol., 31, pp. 50-56McGann, P.T., Ware, R.E., Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? (2011) Curr. Opin. Hematol., 18, pp. 158-165Medinger, M., Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status (2009) Br. J. Haematol., 146, pp. 150-157Minniti, C.P., Leg ulcers in sickle cell disease (2010) Am. J. Hematol., 85, pp. 831-833Minniti, C.P., Laboratory and echocardiography markers in sickle cell patients with leg ulcers (2011) Am. J. Hematol., 86, pp. 705-708Naldini, A., Carraro, F., Role of inflammatory mediators in angiogenesis (2005) Curr. Drug Targets Inflamm. Allergy, 4, pp. 3-8Negrao, R., Angiogenesis and inflammation signaling are targets of beer polyphenols on vascular cells (2010) J. Cell. Biochem., 111, pp. 1270-1279Novelli, E.M., Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates (2012) Am. J. Hematol., 87, pp. 326-330Pakneshan, P., Differential suppression of vascular permeability and corneal angiogenesis by nonsteroidal anti-inflammatory drugs (2008) Invest. Ophthalmol. Vis. Sci., 49, pp. 3909-3913Pandya, N.M., Angiogenesis-a new target for future therapy (2006) Vasc. Pharmacol., 44, pp. 265-274Patel, N., Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD) (2010) J. Biol. Chem., 285, pp. 16713-16722Poliseno, L., MicroRNAs modulate the angiogenic properties of HUVECs (2006) Blood, 108, pp. 3068-3071Ribatti, D., Angiogenesis in asthma (2009) Clin. Exp. Allergy, 39, pp. 1815-1821Rippe, C., MicroRNA changes in human arterial endothelial cells with senescence: relation to apoptosis, eNOS and inflammation (2012) Exp. Gerontol., 47, pp. 45-51Saraceno, R., Hydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject (2008) Clin. Ther., 30, pp. 1324-1329Shen, X., Heparin impairs angiogenesis through inhibition of microRNA-10b (2011) J. Biol. Chem., 286, pp. 26616-26627Sirieix, M.E., Leg ulcers and hydroxyurea: forty-one cases (1999) Arch. Dermatol., 135, pp. 818-820Soares, R., Evidence for the notch signaling pathway on the role of estrogen in angiogenesis (2004) Mol. Endocrinol., 18, pp. 2333-2343Suarez, Y., Sessa, W.C., MicroRNAs as novel regulators of angiogenesis (2009) Circ. Res., 104, pp. 442-454Suarez, Y., Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells (2007) Circ. Res., 100, pp. 1164-1173Sundaram, N., High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension (2010) Blood, 116, pp. 109-112Szekanecz, Z., Angiogenesis in inflammation (2010) Encyclopedia of the Eye, , Elsevier Academic, Amsterdam, London, J. Besharse (Ed.)Trelinski, J., Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status (2010) Leuk. Lymphoma, 51, pp. 1727-1733Tuccoli, A., MiRNAs regulate miRNAs: coordinated transcriptional and post-transcriptional regulation (2006) Cell Cycle, 5, pp. 2473-2476Vadlapatla, R.K., Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases (2013) Curr. Drug Targets, 14, pp. 919-935Villani, P., Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I (1996) J. Clin. Pharmacol., 36, pp. 117-121Ware, R.E., Aygun, B., Advances in the use of hydroxyurea (2009) Hematol. Am. Soc. Hematol. Educ. Program.Woo, G.H., Effects of prenatal hydroxyurea-treatment on mouse offspring (2004) Exp. Toxicol. Pathol., 56, pp. 1-7Zhang, X., Increased expression of microRNA-221 inhibits PAK1 in endothelial progenitor cells and impairs its function via c-Raf/MEK/ERK pathway (2013) Biochem. Biophys. Res. Commun., 431, pp. 404-408